Atlas Venture Associates Opportunity I, LLC, 10% Owner at Kymera Therapeutics, Inc. (KYMR), sold 761,210 shares at $34.02 ($23.9M) on 2022-12-14, disclosed to the SEC on 2022-12-16.
Scheduled sale ($23.9M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.28 | 112,819 | $3.4M | 14.3% |
| 2 | $30.28 | 31,584 | $956K | 4.0% |
| 3 | $30.28 | 31,584 | $956K | 4.0% |
| 4 | $30.28 | 112,819 | $3.4M | 14.3% |
| 5 | $31.44 | 28,329 | $891K | 3.7% |
| 6 | $31.44 | 28,329 |
| $891K |
| 3.7% |
| 7 | $31.44 | 101,189 | $3.2M | 13.3% |
| 8 | $31.44 | 101,189 | $3.2M | 13.3% |
| 9 | $32.33 | 54,737 | $1.8M | 7.4% |
| 10 | $32.33 | 15,324 | $495K | 2.1% |
| 11 | $32.33 | 15,324 | $495K | 2.1% |
| 12 | $32.33 | 54,737 | $1.8M | 7.4% |
| 13 | $33.34 | 13,997 | $467K | 2.0% |
| 14 | $33.34 | 3,919 | $131K | 0.5% |
| 15 | $33.34 | 3,919 | $131K | 0.5% |
| 16 | $33.34 | 13,997 | $467K | 2.0% |
| 17 | $34.02 | 3,733 | $127K | 0.5% |
| 18 | $34.02 | 3,733 | $127K | 0.5% |
| 19 | $34.02 | 13,335 | $454K | 1.9% |
| 20 | $34.02 | 13,335 | $454K | 1.9% |
| 21 | $30.00 | 717 | $22K | 0.1% |
| 22 | $30.00 | 2,561 | $77K | 0.3% |
| Total | $31.36 avg | 761,210 | $23.9M | 100% |
| Filing → |
| IKNA | BUY | 2021-12-14 | $2.0M | — | Filing → |
| IKNA | SELL | 2021-12-14 | $688K | — | Filing → |
| GBIO | SELL | 2021-06-23 | $9.3M | — | Filing → |